Skip to main content
Top
Published in: Diabetologia 11/2007

01-11-2007 | Short Communication

Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes

Authors: Y. M. Cho, J. T. Kim, K. S. Ko, B. K. Koo, S. W. Yang, M. H. Park, H. K. Lee, K. S. Park

Published in: Diabetologia | Issue 11/2007

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to investigate the prevalence of fulminant type 1 diabetes and the clinical characteristics of the disease among newly diagnosed Korean patients.

Methods

Using data retrieved from the Seoul National University Hospital database, we identified all patients newly diagnosed with type 1 diabetes from 1 January 1999 to 31 July 2006. Information on clinical manifestations and laboratory data, including the presence of islet autoantibodies detected at diagnosis, were obtained by reviewing medical records.

Results

We identified 99 patients newly diagnosed with type 1 diabetes. Seven patients (7.1%) fulfilled the criteria for fulminant type 1 diabetes. Among the patients aged ≥18 years at onset, 30.4% had fulminant type 1 diabetes. Patients with this diabetes subtype tested negative for islet autoantibodies, had a higher age of onset (median 28 vs 10 years, p < 0.001) and a markedly shorter duration from onset of hyperglycaemic symptoms to first hospital visit (median 3 vs 30 days, p < 0.001) than patients with non-fulminant type 1 diabetes, and showed trends of increased serum aspartate aminotransferase and amylase levels and a decreased glucagon-stimulated serum C-peptide response.

Conclusions/interpretation

In Korea, the prevalence of fulminant type 1 diabetes was 7.1% among all patients newly diagnosed with type 1 diabetes and 30.4% among patients with adult-onset diabetes. The clinical and metabolic characteristics of the patients with fulminant type 1 diabetes were similar to those reported in Japanese studies.
Literature
1.
go back to reference Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307CrossRef Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301–307CrossRef
2.
go back to reference Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352CrossRef Imagawa A, Hanafusa T, Uchigata Y et al (2003) Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345–2352CrossRef
3.
go back to reference Maldonado M, Hampe CS, Gaur LK et al (2003) Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab 88:5090–5098CrossRef Maldonado M, Hampe CS, Gaur LK et al (2003) Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab 88:5090–5098CrossRef
4.
go back to reference Pozzilli P, Visalli N, Leslie D (2000) No evidence of rapid onset (Japanese) type I diabetes in Caucasian patients. IMDIAB Group. Diabetologia 43:1332CrossRef Pozzilli P, Visalli N, Leslie D (2000) No evidence of rapid onset (Japanese) type I diabetes in Caucasian patients. IMDIAB Group. Diabetologia 43:1332CrossRef
5.
go back to reference Balasubramanian K, Dabadghao P, Bhatia V et al (2003) High frequency of type 1B (idiopathic) diabetes in North Indian children with recent-onset diabetes. Diabetes Care 26:2697CrossRef Balasubramanian K, Dabadghao P, Bhatia V et al (2003) High frequency of type 1B (idiopathic) diabetes in North Indian children with recent-onset diabetes. Diabetes Care 26:2697CrossRef
6.
go back to reference Jung JH, Hahm JR, Kim MA et al (2005) Fulminant autoantibody-negative and type 1A diabetes phenotypes in a Korean HLA identical dizygotic twin. Diabetes Care 28:2330–2331CrossRef Jung JH, Hahm JR, Kim MA et al (2005) Fulminant autoantibody-negative and type 1A diabetes phenotypes in a Korean HLA identical dizygotic twin. Diabetes Care 28:2330–2331CrossRef
7.
go back to reference Jung TS, Chung SI, Kim MA et al (2004) A Korean patient with fulminant autoantibody-negative type 1 diabetes. Diabetes Care 27:3023–3024CrossRef Jung TS, Chung SI, Kim MA et al (2004) A Korean patient with fulminant autoantibody-negative type 1 diabetes. Diabetes Care 27:3023–3024CrossRef
8.
go back to reference Imagawa A, Hanafusa T (2006) Fulminant type 1 diabetes mellitus. Endocr J 53:577–584CrossRef Imagawa A, Hanafusa T (2006) Fulminant type 1 diabetes mellitus. Endocr J 53:577–584CrossRef
9.
go back to reference Chase HP, MacKenzie TA, Burdick J, et al. (2004) Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes 5:16–19CrossRef Chase HP, MacKenzie TA, Burdick J, et al. (2004) Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes 5:16–19CrossRef
10.
go back to reference Yu J, Shin CH, Yang SW, Park MH, Eisenbarth GS (2004) Analysis of children with type 1 diabetes in Korea: high prevalence of specific anti-islet autoantibodies, immunogenetic similarities to Western populations with “unique” haplotypes, and lack of discrimination by aspartic acid at position 57 of DQB. Clin Immunol 113:318–325CrossRef Yu J, Shin CH, Yang SW, Park MH, Eisenbarth GS (2004) Analysis of children with type 1 diabetes in Korea: high prevalence of specific anti-islet autoantibodies, immunogenetic similarities to Western populations with “unique” haplotypes, and lack of discrimination by aspartic acid at position 57 of DQB. Clin Immunol 113:318–325CrossRef
Metadata
Title
Fulminant type 1 diabetes in Korea: high prevalence among patients with adult-onset type 1 diabetes
Authors
Y. M. Cho
J. T. Kim
K. S. Ko
B. K. Koo
S. W. Yang
M. H. Park
H. K. Lee
K. S. Park
Publication date
01-11-2007
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0812-z

Other articles of this Issue 11/2007

Diabetologia 11/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine